Jasper Therapeutics(US:JSPR) Newsfileยท2025-11-16 02:10Core Points - Rosen Law Firm is reminding investors of Jasper Therapeutics, Inc. about the November 18, 2025 deadline to join a securities class action lawsuit related to the company's stock purchased between November 30, 2023, and July 3, 2025 [1][2] Group 1: Class Action Details - Investors who purchased Jasper Therapeutics securities during the specified class period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2] - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by the November 18, 2025 deadline [3] - The Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions [4] Group 2: Allegations Against Jasper Therapeutics - The lawsuit alleges that Jasper Therapeutics made false and misleading statements regarding its manufacturing controls and compliance with cGMP regulations [5] - It is claimed that these failures increased the risk of confounding results in ongoing studies, negatively impacting the regulatory and commercial prospects of Jasper's products, including briquilimab [5] - The lawsuit asserts that the public statements made by the defendants were materially false and misleading, leading to investor damages when the true details became known [5]